M1 Kliniken AG decides to start share buyback

EQS-Ad-hoc: M1 Kliniken AG / Key word(s): Share Buyback
M1 Kliniken AG decides to start share buyback

26-Apr-2024 / 11:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Publication of inside information pursuant to Article 17 of Regulation (EU)
No 596/2014

M1 Kliniken AG decides to start share buyback

Berlin, 26.04.2024 - The Management Board of M1 Kliniken AG today resolved
to repurchase up to 1,000,000 shares of the Company in a maximum total
volume of EUR 12,600,000.00 (excluding incidental acquisition costs). The
resolution is based on the authorization of the Annual General Meeting of 9
July 2020 to acquire own shares. The buyback program is to start on 29 April
2024 and to be completed by the end of 25 April 2025 at the latest. The
share buyback and the purchase settlement will be carried out exclusively by
a credit institution or an investment firm, which will decide on the timing
of the acquisition of shares independently of and without influence by the
Company. The sole purpose of the share buyback program is to use the
repurchased shares for all purposes provided for in the authorization
resolution of the Company's Annual General Meeting of 9 July 2020 and for
all other purposes permitted by the Company's share law.

The buy-back program and its implementation shall take place in compliance
with the requirements of the safe harbor regulations pursuant to Art. 5
para. 2 of the Market Abuse Regulation (EU) No. 596/2014 and Art. 2, 3 and 4
of the Delegated Regulation (EU) No. 2016/1052, with the exception of the
purpose of the buy-back. This is broader than determined by Art. 5 (2) of
the Market Abuse Regulation.

About M1 Kliniken AG

M1 Kliniken AG is the leading fully integrated provider of aesthetic medical
healthcare services in Europe. The Group offers products and services of the
highest quality standards in the aesthetic and surgical fields. Beauty
medical treatments are currently offered at 61 specialist centres under the
"M1 Med Beauty" brand. With six operating theatres and 35 beds, the "M1
Schlossklinik" for Plastic and Aesthetic Surgery in Berlin is one of the
largest and most modern facilities of its kind in Europe. M1 Kliniken has
been driving forward its internationalisation since the end of 2018 and is
currently represented in ten countries.




Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de


End of Inside Information

---------------------------------------------------------------------------

26-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        M1 Kliniken AG
                   Grünauer Straße 5
                   12557 Berlin
                   Germany
   Phone:          +49 (0)30 347 47 44 14
   Fax:            +49 (0)30 347 47 44 17
   E-mail:         ir@m1-kliniken.de
   Internet:       https://www.m1-kliniken.de
   ISIN:           DE000A0STSQ8
   WKN:            A0STSQ
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt (Basic Board), Hamburg, Hanover, Munich,
                   Stuttgart, Tradegate Exchange
   EQS News ID:    1890651

End of Announcement EQS News Service
---------------------------------------------------------------------------

1890651 26-Apr-2024 CET/CEST